title: Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial.
abstract: OBJECTIVE
  Our purpose was to evaluate the long-term use of sirolimus-eluting stents (SES) and bare-metal stents (BMS) in patients with complex coronary artery lesions.
  
  
  BACKGROUND
  Although the use of SES has proved to be effective in patients with simple coronary artery lesions, there are limited data of the long-term outcome of patients with complex coronary artery lesions.
  
  
  METHODS
  We randomly assigned 322 patients with total coronary occlusions or lesions located in bifurcations, ostial, or angulated segments of the coronary arteries to have SES or BMS implanted.
  
  
  RESULTS
  At 3 years, major adverse cardiac events had occurred in 20 patients (12%) in the SES group and in 59 patients (38%) in the BMS group (p < 0.001). Four versus 2 patients suffered a cardiac death (p = NS), and 5 versus 1 died of a noncardiac disease (p = NS) in the SES versus the BMS group. Six patients in the SES group versus 15 patients in the BMS group suffered a myocardial infarction (p < 0.05) during the 3-year observation period, and target lesion revascularization was performed in 8 patients (4.9%) versus 53 patients (33.8%), respectively (p < 0.001); of these, 4 in the SES versus 7 in the BMS group were performed between 1 and 3 years after the index treatment (p = NS). According to revised definitions, stent thrombosis occurred in 5 patients (3.1%) in the SES group and in 7 patients (4.4%) in the BMS group (p = NS); very late stent thrombosis was observed in 4 versus 1 patient.
  
  
  CONCLUSIONS
  A continued benefit was observed up to 3 years after implantation of SES in patients with complex coronary artery lesions. The rate of late adverse events was similar in the 2 groups, and stent thromboses occurred rarely after 1 year. (Sirolimus Eluting Stents in Complex Coronary Lesions [SCANDSTENT]; NCT00151658)
authors.affiliation: Rigshospitalet, Copenhagen, Denmark. henning.kelbaek@rh.regionh.dk
authors.forename: Henning
authors.initials: H
authors.lastname: Kelbaek
authors.forename: Lene
authors.initials: L
authors.lastname: Kløvgaard
authors.forename: Steffen
authors.initials: S
authors.lastname: Helqvist
authors.forename: Jens F
authors.initials: JF
authors.lastname: Lassen
authors.forename: Lars R
authors.initials: LR
authors.lastname: Krusell
authors.forename: Thomas
authors.initials: T
authors.lastname: Engstrøm
authors.forename: Hans E
authors.initials: HE
authors.lastname: Bøtker
authors.forename: Erik
authors.initials: E
authors.lastname: Jørgensen
authors.forename: Kari
authors.initials: K
authors.lastname: Saunamäki
authors.forename: Samir
authors.initials: S
authors.lastname: Aljabbari
authors.forename: Per
authors.initials: P
authors.lastname: Thayssen
authors.forename: Anders
authors.initials: A
authors.lastname: Galløe
authors.forename: Gunnar V H
authors.initials: GV
authors.lastname: Jensen
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D003327:Coronary Disease / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D020123:Sirolimus